SCHEMBL3071763

SCHEMBL3071763

CCOC(=O)N1CCC2Cc3c(C)cc(Br)cc3C2C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 2/20 0.39
ALOX12 P18054 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 2/20 0.38
ALDH1A1 P00352 2/20 0.38
DPP4 P27487 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
PDE4B Q07343 1/20 0.37
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3071759 1.00 MAPK1 (0.40) MAPK1MEN1KMT2AKDM4EHSD17B10
SCHEMBL3086550 0.82 ALDH1A1 (0.42) MEN1KMT2AKDM4EHSD17B10GAA
SCHEMBL3086546 0.82 ALDH1A1 (0.42) MEN1KMT2AKDM4EHSD17B10GAA
SCHEMBL12430160 0.81 POLB (0.41) MAPK1KMT2AKDM4EHSD17B10GAA
SCHEMBL3077446 0.81 ALDH1A1 (0.47) MEN1KMT2AKDM4EGAAALOX12
SCHEMBL3077450 0.81 ALDH1A1 (0.47) MEN1KMT2AKDM4EGAAALOX12
SCHEMBL3078772 0.78 MEN1 (0.45) MEN1KMT2AKDM4EGAAALDH1A1
SCHEMBL3078768 0.78 MEN1 (0.45) MEN1KMT2AKDM4EGAAALDH1A1
SCHEMBL3065447 0.74 MEN1 (0.40) MAPK1MEN1KMT2AKDM4EGAA
SCHEMBL3065444 0.74 MEN1 (0.40) MAPK1MEN1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795436-B2 Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-14 US disclosed
US-20070049613-A1 Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049613-A1 Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists HTR2B, HTR2C, HTR1A MAPK1 2475/4885MEN1 2162/4885KMT2A 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.